非小细胞肺癌术后支气管残端复发

目的：研究支气管残端复发率与组织病理学及肿瘤分期的关系；探讨CT在肺癌术后随访中的应用价值。方法：我院1999年1月～2008年3月1384例非小细胞肺癌患者根治术后，有277例患者出现局部复发，其中临床和影像资料完整的36例患者为支气管残端复发。依据组织学和肿瘤分期分析局部复发及支气管残端复发的情况，并评价支气管残端复发的CT表现。结果：277例局部复发病例中，支气管残端复发者36例（13％）。支气管残端复发经支气管镜检组织学证实者11例，临床和随访胸部CT诊断25例。复发时临床症状表现血痰10例（27．8％），咳嗽7例（19．4％），呼吸困难2例（5．6％），胸痛2例（5．6％），15例（41．6％）无任何症状。支气管残端复发中鳞癌22例，腺癌12例，大细胞癌2例。支气管残端复发率鳞癌（3．1％）高于腺癌（1．9％）（P=0．195）。支气管残端复发病例中，肿瘤术后复发前分期为Ib期7例，Ⅱa期3例，Ⅱb期11例，Ⅲa期12例，Ⅲb期3例。胸部CT显示支气管残端复发影像表现为残端支气管管壁增厚19例（52．8％）；残端附近见软组织肿物17例（47．2％）。手术至胸部CT发现支气管残端复发的时间间隔为5～91个月（中位20．6个月），其中28例患者（77．8％）24个月（2年）内胸部CT发现支气管残端复发。结论：非小细胞肺癌根治术后约2．6％患者发生支气管残端复发，其发生率鳞癌高于腺癌。支气管残端复发的CT表现为残端支气管管壁增厚和残端附近形成软组织肿物。术后定期胸部CT检查和支气管镜检能及早发现复发。     

^18F-FDG PET／CT显像监测胃癌术后复发转移的价值

目的评价^18F-脱氧葡萄糖（FDG）PET／CT监测胃癌术后复发及转移的临床价值。方法回顾性分析胃癌术后临床疑复发或转移而行^18F-FDG PET／CT检查的45例患者临床资料,根据细胞学、病理或随访结果分析PET／CT检查结果,计算残胃及转移灶最大标准摄取值（SUVmax）。采用SPSS11．5软件进行数据处理,SUVmax两样本均数比较采用t检验。结果（1）45例中22例临床疑残胃复发,12例患者最终确定残胃复发,^18F-FDG PET／CT诊断残胃复发的灵敏度、特异性及准确性分别为100．0％（12／12）、70．0％（7／10）和86．4％（19／22）,12例复发病灶SUVmax为6．27±3．42（其中2例低分化腺癌的SUVmax较低,分别为2．5和3．3）,另10例无复发的残胃SUVmax为3．92±2．24（其中3例吻合口炎性病灶局部SUVmax较高,分别为8．3,5．2和6．3）,差异无统计学意义（t=1．862,P〉0．05）。（2）对残胃以外转移灶的检出：PET／CT灵敏度、特异性、准确性在区域淋巴结转移中分别为78．9％（15／19）、92．3％（24／26）和86．7％（39／45）,在腹膜转移中分别为6／9、97．2％（35／36）和91．1％（41／45）,在远处转移中分别为86．7％（13／15）、93．3％（28／30）和91．1％（41／45）。（3）PET／CT假阳性8处为炎性或肠管摄取,假阴性9处多为直径〈1．0cm的转移灶和低分化腺癌及印戒细胞癌的转移灶。结论^18F-FDG PET／CT虽然检测胃癌术后区域淋巴结和腹膜转移的灵敏度较低,但仍是监测其术后复发转移的有效手段。     

直肠癌Miles手术后局部复发原因及治疗

目的探讨直肠癌Miles术后局部复发的原因及防治。方法1986年1月-2006年12月共行直肠癌Miles手术218例．对其中术后局部复发35例的临床情况进行回顾性分析。结果局部复发35例中男26例，平均年龄比首次手术组低5岁，DukesC期25例，组织学高度恶性19例，22例肿瘤距肛门3-6cm。复发再手术14例，5年生存率为27．2％（4／14），中位生存期25．4个月（5—144个月）；单纯放化疗21例，中位生存期11．7个月（3—29个月），未手术者均在3年内死亡。结论术后局部复发与年龄、性别、病期、病理类型、肿瘤部位及根治是否彻底密切相关。预防复发宜做好首次手术。对复发病例力争早发现，并予再次手术为主的综合治疗，以延长生存期。     

TME联合125I粒子植入治疗中下段直肠癌

目的探讨全直肠系膜切除（TME）联合^125I粒子术中植入治疗进展期中下段直肠癌的效果。方法67例中下段直肠癌TME手术根治患者（均为Dukes’B、C期），分成3组：①组：TME手术根治加化疗组24例；②组：TME手术根治加放疗组18例；③组：TME手术根治联合^125I粒子植入组19例。跟踪随访2年内复发率；同时比较②与③组并发症的发生情况。结果3组1．5年内复发率分别为46％、11％和5％；②、⑧组复发率低于①组（x^2=4．291、6．771，P〈0．05），③组复发率与②组相比差异无显著性；但⑧组并发症的发生率（10％）比②组（44％）明显降低（确切概率计算法，P=0．029）。结论TME联合^125II粒子术中植入有助于预防直肠癌术后复发，且并发症的发生率低。     

胃癌术后复发X线B超诊断（附18例分析）

胃癌术后复发的18例，发病年龄在45－70岁之间，术后复发l－10年不等，主要症状以腹痛、乏力、贫血进行性消瘦等临床表现。X线钡餐表现：（1）吻合口改变，在18例中，其中3例残胃吻合口复发，X线表现为吻合回延长，狭窄、僵硬，1例形成吻合口梗阻。（2）残胃局部淋巴结复发转移4例，钡透检查时在贲门周围及小弯侧出现园形较浅弧形压迹，局部粘膜变平，残胃固定（图1）。（3）肠系膜转移改变5例，主要表现为肠间距增宽，排空明显增快，部分钡剂呈分节改变。B超表现：（1）吻合口周围改变8例，主要在左上腺是不规则的包块，似假肾征，中央有…     

原发性肝癌外科手术联合血管内介入治疗的意义

目的：探讨原发性肝癌外科联合血管内介入治疗的意义。方法：69例原发性肝癌患者,41例先行手术切除,术后行TAI或TACE;28例先行TACE,7天-1月内再行手术切除,术后1—6月内再行TAI或TACE治疗。结果：全组病例共行236次TM或TACE,最多者11次,最少者1次,平均3．4次。手术及介入治疗均成功,未出现并发症。先行手术组1～2个月造影残癌者9例（9／41）,2年内发现复发病灶18例。先行TACE组手术后近期未发现残余病灶,2年内肿瘤复发为7例。AFP术后降至正常或接近正常范围为56例,术后存活率为：半年100％,1年89．3％,2年68．0％,3年57．3％,5年43．8％。结论：术前行TACE有利于争取手术机会和手术根治,防止术后复发。介入治疗和手术结合是提高肝癌整体疗效及病人存活率的重要方法。     

三种复发性喉乳头状瘤治疗方法的疗效分析

目的探讨复发性喉乳头状瘤的有效治疗方法。方法回顾性分析我院2000年1月～2005年12月诊治的67例复发性喉乳头状瘤患者的临床资料。结果67例中未成年患者组47例，占70．1％；成年患者组20例，占29．9％。行喉造口喉乳头状瘤激光切除术34例，16例复发（未成年患者13例，成年患者3例），占47．1％；术后喉狭窄15例（未成年患者12例，成年患者3例），其中9例为再次复发者。行喉部分切除术3例，随访2年未再复发，且均无喉狭窄出现。行支撑喉镜下喉乳头状瘤CO：激光切除术30例，复发7例，占23．3％；术后喉狭窄6例（均为未成年患者）。术后复发23例中，未成年患者20例占87．0％；成年患者复发3例占13．0％。不同术式的术后复发率及喉狭窄发生率差别有统计学意义（均P〈0．05）；不同年龄组的术后复发率及喉狭窄发生率虽有差异，但无显著意义（P〉0．05）。结论支撑喉镜下喉乳头状瘤CO2激光切除术及术后定期复查是目前较为有效的治疗复发性喉乳头状瘤的方法。     

套入式结肠直肠黏膜吻合保肛术治疗中低位直肠癌208例报告

目的 探讨套入式结肠直肠黏膜吻合保肛术式治疗中低位直肠癌的临床疗效。方法 对208例中低位直肠癌行套入式结肠直肠黏膜吻合保肛术式经腹肛门根治性切除病例进行回顾性分析。208例中男131例,女77例,年龄21～99岁,平均53．7岁。肿瘤下缘距齿状线6～8cm。Dukes分期A期76例,B期122例,C期10例。病理诊断直肠腺癌201例,其中高分化者86例,中分化者100例,低分化者8例,黏液腺癌7例。腺瘤癌变7例。结果 208例术后随访率为87．5％（182／208）,中位随访时间5．9年。术后发生吻合口瘘8例（3．8％）,吻合口狭窄3例（1．4％）,排便功能在术后12～24周时基本恢复到正常,每日1～3次。术后局部复发率为4．9％（9／182）,肝转移率为14．2％（26／182）,5年生存率为72．5％。结论 套入式结肠直肠黏膜吻合保肛术式既能保持良好的肛门排便控制功能,又能降低吻合口瘘发生率,局部复发率和5年生存率与Miles手术相同,是一种安全有效的保肛术式。     

早期胃癌淋巴结转移多因素分析

目的探讨早期胃癌淋巴结转移规律,为微创治疗、缩小手术范围提供依据。方法对解放军总医院1983-2005年间诊治的308例早期胃癌患者进行回顾性分析,其中282例术后找到淋巴结,对其年龄,性别,肿瘤大小、部位、大体类型、分化程度、浸润深度,淋巴管癌栓,癌旁黏膜萎缩、肠化、异型增生等与淋巴结转移的关系进行单因素及多因素分析。结果早期胃癌淋巴结转移率为9．9％（28／282）,黏膜（M）癌淋巴结转移率为2．5％（4／157）,黏膜下层（SM）癌淋巴结转移率为19．2％（24／125）。Logistic回归分析提示,淋巴管癌栓（P=0．000,OR=8．568）、浸润黏膜下层（P=0．018,OR=4．234）、肿瘤〉2cm（P=0．020,OR=4．12）、分化不良（P=0．040,OR-2．710）为淋巴结转移的独立危险因子。进一步分层分析提示,影响M癌淋巴结转移的因素为肿瘤大小、淋巴管癌栓,≤2cm的M癌不论分化程度如何均无淋巴管癌栓,也无淋巴结转移（0／108）,2-4cm、无淋巴管癌栓的M癌不论分化程度如何均无淋巴结转移（0／26）;影响SM癌淋巴结的因素为肿瘤大小、组织学类型、淋巴管癌栓,≤2cm、分化良好型、无淋巴管癌栓的SM癌均无淋巴结转移（0／25）,2era、分化不良型、有淋巴管癌栓的SM癌淋巴结转移率72．7％（8／11）。结论肿瘤大小、淋巴管癌栓与M癌淋巴结转移相关,肿瘤大小、组织学类型、淋巴管癌栓与SM癌淋巴结转移相关。     

吡柔比星与卡介苗膀胱灌注预防浅表性膀胱肿瘤复发的比较

目的：对单独应用吡柔比星（THP）、卡介苗（BCG）与二者联合膀胱内灌注预防浅表性膀胱肿瘤复发的疗效进行比较。方法：111例膀胱乳头状移行上皮细胞癌患者行经尿道电切术（TURBT）或膀胱部分切除术,术后随机分为3组：（1）THP组33例,术后1W内单次应用THP100mg膀胱内灌注;（2）BCG组36例,术后1W内开始单用BCG定期膀胱内灌注治疗;（3）联合组42例,术后1W内单次应用THP1130mg膀胱内灌注,从第2W开始应用BCG定期膀胱腔内灌注。每3个月进行膀胱镜、尿脱落细胞学检查,随访12—24个月。结果：THP组5例复发,复发率15．16％（5／33）;BCG组5例复发,复发率13．89％（5／36）;联合组1例复发,复发率2．38％（1／42）。BCG组与THP组复发率比较差异无统计学意义（P〉0．05）,但二者单独与联合组复发率比较组间差异显著（P〈0．05）。3组均无严重不良反应和并发症。结论：联合应用THP、BCG疗效优于各自单独应用,对预防浅表性膀胱肿瘤的复发疗效好,有较高的临床应用价值。     

MRI在胃癌术后复发诊断中的应用价值

目的:探讨MRI在胃癌术后复发诊断中的价值及临床意义.方法:选择2组胃癌术后患者,胃癌术后复发组33例,未复发对照组10例,均经胃镜活检、病理检查证实.2组病例均应用1.5 T MRI行TSE DRIVE/T2WI、T1-FFE T1WI等序列及动态增强扫描检查,测量残胃壁及吻合口胃壁厚度,观察吻合口胃壁MRI常规序列及动态增强信号变化.结果:未复发对照组残胃壁厚度(4.5±0.3)mm,吻合口胃壁厚度(6.3±1.4)mm;术后复发组残胃吻合口胃壁增厚＞8 mm 30例,吻合口邻近胃壁厚度＞5 mm 19例,吻合口软组织肿块并邻近胃壁增厚11例,肝脾胰腺等周围脏器转移5例,肝胃之间、腹腔、腹膜后淋巴结转移9例.病灶在动脉期不均匀强化9例,静脉期及平衡期病灶呈渐进性、延迟强化30例.结论:MRI能够较好地显示残胃壁及吻合口胃壁的厚度,准确判断肿瘤浸润深度及与周围组织毗邻关系、是否有淋巴结和腹腔内脏器转移等,可指导临床选择手术方案或综合治疗,对提高胃癌术后生存率具有重要的临床意义.     

Current status of radiation therapy--evidence-based medicine (EBM) of radiation therapy. Current management of patients with esophageal cancer

The best management for small mucosal esophageal cancer is generally endoscopic mucosal resection. However, for submucosal cancer and extensive mucosal cancer, either radical surgery or radiation seems to be an equally efficacious option. Radiation therapy concurrent with chemotherapy is more effective than radiation therapy alone for patients with unresectable esophageal cancer. The key drugs are cisplatin and 5-fluorouracil. However, for patients with poor performance status or for aged patients, radiation therapy alone is still a choice of treatment. Surgery has generally been indicated for patients with resectable esophageal cancer. However, outcomes of concurrent chemoradiation therapy may be comparable with those of surgery. Therefore, a prospective randomized study should be performed to determine the best management for patients with resectable esophageal cancer. The usefulness of intra-cavitary irradiation for esophageal cancer has not been clarified. A prospective randomized trial with a large number of patients is necessary to determine the effectiveness of intra-cavitary irradiation. The best management for patients with loco-regionally recurrent esophageal cancer after surgery has not been determined. Intensive therapy should be considered if the site of recurrence is limited and the time interval from surgery to recurrence is long. Chemotherapy is essential in the management of patients with small cell esophageal cancer. However, the best local therapy has not been determined.     

FDG-PET improves the staging and selection of patients with recurrent colorectal cancer

Whole-body fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) has proved effective in the diagnosis and staging of recurrent colorectal cancer. In this study, we analysed how PET affects the management of patients with recurrent colorectal cancer by permitting more accurate selection of candidates for curative resection. The data of 79 patients with known or suspected recurrent colorectal cancer were analysed. Conventional imaging modalities (CIM) and PET results were compared with regard to their accuracy in determining the extent and the resectability of tumour recurrence. Recurrence was demonstrated in 68 of the 79 patients. The data indicate that PET was superior to CIM for detection of recurrence at all sites except the liver. Based on the CIM+PET staging, surgery with curative intent was proposed in 39 patients and was indeed achieved in 31 of them (80%). PET was more accurate than CIM alone in predicting the resectability or non-resectability of the recurrence (82% vs 68%, P=0.02). It is concluded that whole-body FDG-PET is highly sensitive for both the diagnosis and the staging of patients with recurrent colorectal cancer. Its use in conjunction with conventional imaging procedures results in a more accurate selection of patients for surgical treatment with curative intent.     

The role of gastric distention in differentiating recurrent tumor from physiologic uptake in the remnant stomach on 18F-FDG PET.

Physiologic (18)F-FDG uptake in the stomach can often cause false-positive results and lowers the usefulness of (18)F-FDG PET in evaluating the remnant stomach. We assessed the role of gastric distension to see whether it is beneficial for the differentiation of recurrent tumors from physiologic (18)F-FDG uptake in the remnant stomach. METHODS: Thirty patients (22 men and 8 women; age range, 27-80 y; mean age, 58.3 y) with a history of subtotal gastrectomy for gastric cancer underwent (18)F-FDG PET for various clinical indications. After whole-body imaging, the patients were asked to drink water, and then spot imaging of the stomach was performed. (18)F-FDG uptake in the remnant stomach was considered positive for malignancy if it was persistently increased, whether focal or diffuse, after water ingestion. We used 2 standardized uptake value (SUV) criteria to differentiate benign from malignant uptake. First, a lesion was considered benign if its SUV was less than 2 on whole-body imaging. Second, for a lesion with an SUV of 2 or above, it was classified as benign if SUV decreased by more than 10% after water ingestion. RESULTS: Visual analysis of whole-body images produced 9 true-negative, 4 false-positive, 16 true-positive, and 1 false-negative results. Use of additional spot images produced 12 true-negative, 1 false-positive, 15 true-positive, and 2 false-negative results. When an SUV cutoff of 2 was applied for malignancy before water ingestion, all 17 patients with local recurrence were correctly identified, but 11 of the 13 patients without local recurrence were falsely considered to have a recurrent tumor in the remnant stomach. To reduce the false-positive results, we used the second SUV criterion after water ingestion. Use of that criterion produced 4 false-negative results although it correctly identified the 11 false-positive results as true negative. CONCLUSION: Gastric distension by having patients drink a glass of water seems to be a simple, cost-effective way of improving the diagnostic accuracy of (18)F-FDG PET in patients with suspected recurrence in the remnant stomach. Visual analysis with special attention to the configuration of (18)F-FDG activity after water ingestion seems to be more useful than the change in SUV in evaluating the remnant stomach.     

内镜超声对早期胃癌内镜下治疗的指导价值

目的探讨内镜超声（EUS）对内镜下黏膜切除术（EMR）及内镜黏膜下剥离术（ESD）治疗早期胃癌（EGC）的指导价值。方法 56例EGC患者事先行EUS检查后,行EMR或ESD治疗,作为研究组;未行EUS检查的32例行EMR或ESD治疗的EGC患者作为对照组。统计EUS对病灶大小、浸润深度及淋巴结转移的检查情况,比较两组病灶切除情况、手术并发症、5年复发率及生存率。结果研究组56例患者经EUS检查后,发现m癌36例,sm癌20例;与病理结果对照,m癌诊断符合率94.4%,sm癌符合率90.0%;无论是EMR还是ESD,研究组的整块切除率、完整切除率及治愈性切除率均显著高于对照组（P〈0.05或P〈0.01）,非治愈性切除率显著低于对照组（P〈0.05）。研究组术后5年内复发率（3.57%）显著低于对照组（18.75%）（P〈0.05）,5年存活率（98.21%）显著高于对照组（87.50%）（P〈0.05）。结论 EUS有助于EGC患者EMR或ESD适应证的选择,能指导术者对切除范围的了解,保证切除效果和安全性,提高了EGC内镜下治疗效果。     

高场强MRI在胃癌术后复发诊断中的应用价值

目的 探讨高场强MRI在胃癌术后复发诊断中的应用价值及临床意义。方法 选择胃癌术后患者43例。其中,胃癌术后复发组33例,均经过消化道钡餐、CT、手术或胃镜活检和病理检查确诊;对照组10例,均经胃镜活检及病理检查证实无复发。MRI检查前使用低张剂,服用水做为阴性对比剂,应用1.5TMR快速扰相梯度回波序列、快速恢复自旋回波序列、扩散加权成像、真稳态进动快速序列等及动态增强扫描检查方法。结果 MRI诊出胃癌术后复发患者30例。对照组残胃壁厚度(4.5±0.3) mm,吻合口胃壁厚度(6.3±1.4) mm;复发组残胃吻合口胃壁增厚>8mm者30例,吻合口邻近胃壁厚度>5 mm者19例,吻合口软组织肿块并邻近胃壁增厚者11例,肝脾胰腺等周围脏器转移者5例,肝胃之间、腹腔、腹膜后淋巴结转移者9例,病灶在动脉期不均匀强化者9例,静脉期及平衡期病灶呈渐进性、延迟强化者30例。结论 MRI较好地显示了残胃壁及吻合口胃壁的厚度,能够准确判断肿瘤浸润深度、是否与周围组织有毗邻关系以及是否有淋巴结和腹腔内脏器转移等,可以用来指导临床手术方案的选择或综合治疗,对提高胃癌术后生存率具有重要的临床意义。     

Chemoradiotherapy for patients with recurrent lymph-node metastasis or local recurrence of gastric cancer after curative gastrectomy

Objectives

Whether chemoradiotherapy (CRT) is clinically beneficial for the management of postoperative recurrence of advanced gastric cancer remains unclear. We retrospectively studied treatment outcomes in patients who had unresectable localized recurrence after surgery for advanced gastric cancer and evaluated the safety and efficacy of CRT.

Methods

The study group comprised 21 patients who received concurrent CRT for unresectable localized recurrence after undergoing R0 resection for stage II/III advanced gastric cancer. Localized recurrence was defined as a few or limited recurrent lesions.

Results

The recurrence pattern was anastomotic recurrence in 7 patients, abdominal lymph-node recurrence in 12, and anastomotic recurrence plus abdominal lymph-node recurrence in 2. The median total dose of radiotherapy was 48.6 Gy (range 39.6–56.0), and the CRT completion rate was 100 % (21 of 21 patients). CRT-related grade 3 or higher toxicity comprised neutropenia in 33.3 % of patients and anorexia in 9.5 %. The response rate was 61.9 % (complete response 38.1 %, partial response 23.8 %). The median overall survival was 35.0 months.

Conclusions

We conclude that CRT may become one treatment strategy for the management of unresectable localized recurrence after curative resection of advanced gastric cancer.

     

进展期胃癌介入治疗疗效分析

目的研究进展期胃癌的介入治疗及疗效。方法对212例进展期胃癌进行介入治疗。对贲门癌经胃左动脉和左膈下动脉或脾动脉进行化疗灌注和胃左动脉栓塞;对胃体小弯侧癌经胃左、右动脉或肝总动脉,对胃大弯侧癌经胃十二指肠动脉、胃网膜右动脉或脾动脉化疗灌注;对胃窦癌经胃十二指肠动脉或对胃网膜右动脉中段栓塞后进行化疗药物灌注。对胃癌复发和残胃癌经腹腔干和肠系膜上动脉化疗灌注。结果对未手术的193例胃癌的疗效为贲门癌CR PR53.1%,胃体癌CR PR44.4%,胃窦癌CR PR10.0%,胃癌复发和残胃癌CR PR0。贲门癌与胃体癌有效率相比(P>0.25),两者差异无统计学意义。贲门癌与胃窦癌相比及胃体癌与胃窦癌相比,差异有统计学意义(P值均<0.05)。介入治疗后手术切除者术后1、2年生存率分别为81%、56%。结论胃癌在胃组织的发病部位不同,其疗效也不同,贲门癌和胃体癌的疗效较好,胃窦癌及胃癌复发和残胃癌疗效较差。     

Diagnostic performance of FDG PET/CT for surveillance in asymptomatic gastric cancer patients after curative surgical resection

Purpose

The present study evaluated the diagnostic performance of 2-[¹⁸F] fluoro-2-deoxy-d-glucose (FDG) positron emission tomography/computed tomography (PET/CT) for surveillance in asymptomatic gastric cancer patients after curative surgical resection.

Methods

We retrospectively recruited 190 gastric cancer patients (115 early gastric cancer patients and 75 advanced gastric cancer patients) who underwent 1-year (91 patients) or 2-year (99 patients) postoperative FDG PET/CT surveillance, along with a routine follow-up program, after curative surgical resection. All enrolled patients were asymptomatic and showed no recurrence on follow-up examinations performed before PET/CT surveillance. All PET/CT images were visually assessed and all abnormal findings on follow-up examinations including FDG PET/CT were confirmed with histopathological diagnosis or clinical follow-up.

Results

During follow-up, 19 patients (10.0 %) developed recurrence. FDG PET/CT showed abnormal findings in 37 patients (19.5 %). Among them, 16 patients (8.4 %) were diagnosed as cancer recurrence. Of 153 patients without abnormal findings on PET/CT, three patients were false-negative and diagnosed as recurrence on other follow-up examinations. The sensitivity, specificity, positive predictive value, and negative predictive value of FDG PET/CT were 84.2 %, 87.7 %, 43.2 %, and 98.0 %, respectively. Among 115 early gastric cancer patients, PET/CT detected recurrence in four patients (3.5 %) and one patient with local recurrence. Among 75 advanced gastric cancer patients, PET/CT detected recurrence in 12 patients (16.0 %), excluding two patients experiencing peritoneal recurrence. In addition, FDG PET/CT detected secondary primary cancer in six (3.2 %) out of all the patients.

Conclusions

Post-operative FDG PET/CT surveillance showed good diagnostic ability for detecting recurrence in gastric cancer patients. FDG PET/CT could be a useful follow-up modality for gastric cancer patients, especially those with advanced gastric cancer. However, further careful evaluation is needed because of false-positive findings on PET/CT.